Cardiff Oncology (NASDAQ:CRDF) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) released its quarterly earnings results on Thursday. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02, Zacks reports. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.08 million. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.

Cardiff Oncology Stock Down 1.6%

Shares of CRDF traded down $0.01 during mid-day trading on Friday, hitting $0.72. The stock had a trading volume of 103,672 shares, compared to its average volume of 1,023,145. The company has a market cap of $55.70 million, a PE ratio of -1.19 and a beta of 1.57. The company’s fifty day simple moving average is $1.05 and its two-hundred day simple moving average is $1.36. Cardiff Oncology has a fifty-two week low of $0.71 and a fifty-two week high of $3.31.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CRDF shares. HC Wainwright upgraded Cardiff Oncology from a “neutral” rating to a “buy” rating in a report on Tuesday, September 15th. Wall Street Zen upgraded Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings upgraded Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Finally, William Blair downgraded shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Cardiff Oncology Company Profile

Cardiff Oncology is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy. The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment.